Results 211 to 220 of about 41,259 (301)

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

British Journal of Haematology, EarlyView.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis   +18 more
wiley   +1 more source

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis. [PDF]

Nat Genet
Chan ICC, Zhang P, Pan X, Castro C, Fox N, Lewis AM, Weis K, Cuibus A, Tittley S, Petrone G, Beeler JS, Tran D, Mustion G, Fronick C, Stopsack KH, Cruchaga C, Abdel-Wahab O, Bolton KL.   +17 more
europepmc   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years. [PDF]

Blood Adv
Liu Q, Fang F, Xue H, Wästerlid T, Smedby KE, Liu X.   +5 more
europepmc   +1 more source

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B‐Cell‐Specific Somatic MYD88 Mutation

Allergy, EarlyView.
Yuyi Zhou, Yoko Ueki, Naoya Iwata, Hiroshi Oue, Kentaro Kato, Mengyan Li, Kazushi Izawa, Tomoyasu Jo, Seishi Ogawa, Kenji Kabashima, Naotomo Kambe   +10 more
wiley   +1 more source

Integrated proteomic and metabolomic profiling reveals sex‐stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia

British Journal of Haematology, EarlyView.
Construction of the immune thrombocytopenia (ITP) chronicity prediction model was based on sex‐stratified multi‐omics analysis, identifying key sex‐specific predictors (intercellular adhesion molecule‐1 [ICAM‐1] and biopterin in males; actin, alpha 2, smooth muscle, aorta [ACTA‐2] and N6‐acetyl‐L‐lysine in females).
Yuanyuan Xue, Rongrong Zhang, Dongmei Liang, Yupeng Xu, Zhaofang Tian, Xiaohong Dai, Wei Xu, Qingqing Cao, Haiyan Zhu, Yun Wang, Yufang Yuan   +10 more
wiley   +1 more source

When Binding Is Not Blockade: Interpreting IgG4+ T Cells After PD‐1 Therapy

Cancer Science, EarlyView.
IgG4 positivity on circulating T cells after PD‐1 therapy may indicate residual antibody binding rather than sustained functional PD‐1 blockade. During sequential ramucirumab plus docetaxel plus G‐CSF treatment, peripheral IgG4+ T‐cell dynamics may also be influenced by redistribution and treatment‐related confounders, limiting direct inference about ...
Man Sun, Dan Zang, Jun Chen
wiley   +1 more source

Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Cosentino C, Mouhssine S, Zucchetto A, Romano I, Salehi M, Cappelli LV, Iannelli F, Almasri M, Maher N, Fumagalli L, Cardinali D, Visentin A, Nabki J, Cividini L, Al Deeban B, Lazzaro M, Maiellaro F, Gaglio A, Perutelli F, Griggio V, Dondolin R, Bellia M, Nicolosi M, Rasi S, Secomandi E, Caneparo V, Mahmoud AM, Deambrogi C, Kogila S, Ghanej J, Nawabi MR, Del Giudice I, Albi E, Vitale C, Scarfò L, Coscia M, Trentin L, Pileri S, Ghia P, Chiarle R, Gattei V, Terzi di Bergamo L, Rossi D, Foà R, Gaidano G, Moia R.   +45 more
europepmc   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis. [PDF]

Cell Chem Biol
Kim PG, Hergott CB, Miller AP, Deik A, Boileau M, Bullock K, Pierce KA, Choy AH, Shin W, McConkey M, Loke J, Ryback BA, Trinh MN, Rutter JC, Yue H, Yoon H, Park P, Roy Burman SS, Vander Heiden MG, Fischer ES, Armstrong SA, Clish C, Ebert BL.   +22 more
europepmc   +1 more source